Syntimmune, Inc. Report issue

For profit Phase 1
Founded: Boston MA United States (2013)
Status: Acquired by Alexion (2018) → now AstraZeneca (2020)

Organization Overview

First Clinical Trial
2016
NCT03643627
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2017

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Syntimmune, Inc.

Active Ingredients

Drugs in Phase 1 Trials (1)

alxn1830 (3 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Anemia (Phase 1)

Anemia, Hemolytic (Phase 1)

Anemia, Hemolytic, Autoimmune (Phase 1)

Hemolysis (Phase 1)

Pemphigus (Phase 1)

Overview

  • Highest Phase: Phase 1
  • # of Trials: 3
  • # of Trial APIs: 1